Biohacking, simply put, is do-it-yourself (DIY) biology; it gives everyone — individuals, communities, small group organizations, not just research institutions — the ability to deconstruct and reconstruct biology using simple kits or supplements for the purpose of not only achieving their immediate outcomes, but also contributing to solving larger issues.
As an emerging industry and social movement, biohacking represents a new frontier in the development of drugs and therapeutics, and consequently, is a market expected to see exceptionally high growth over the next five years.
This BCC Research special report offers an overview of biohacking, and how this growing industry can spur the interest of prospective investors, large corporations and everyday hackers who could be inspired uncover the next big medical breakthrough.
- Explanation of Biohackers - ‘subculture of people with a whole range of different backgrounds…driven by a pioneering spirit,’ (who) ‘want to liberate themselves from the limitations of nature, age and disease.’
- Segmentation of the global biohacking market by type as outside and inside biohacking. Product-wise, the market is segmented into strains, sensors, smart drugs, and others. Major applications include synthetic biology, forensic science, genetic engineering, diagnosis & treatment, drug testing, and others. End-users in the market include pharmaceutical & biotechnology companies, forensic laboratories, and others
- Outline of how companies such as 23andMe provide direct-to-consumer genetics that with just a saliva drop provides consumers with access to personal health data
- Discussion of a number of key players conducting biohacking awareness drives to help the adults understand the basics to biohacking, and thereby encourage new inventions
- Comprehensive profiles of the noteworthy market players, including Thync Global Inc. (U.S.), Synbiota (Canada), Apple (U.S.), HVMN, Inc. (U.S.), MoodMetric (U.S.), THE ODIN (U.S.), and Fitbit, Inc. (U.S.)
The analyst of this report, Smruti Munshi, has specialized in the medical technologies space for more than five years. She focuses on monitoring and analyzing emerging trends, technologies, competitive benchmarking, and market dynamics in the medical imaging industry. She has worked on several projects spanning the EMEA markets, ranging from market insights, industry overviews, to comprehensive marketing and technology-oriented custom consulting. Ms. Munshi has an MS in Biomedical Engineering and a BS in Instrumentation and Control Engineering. She has authored several reports for BCC Research in the medical field.